Updates are available Correction dated 2025-08-21
Click to view Correction: https://doi.org/10.1038/s41589-025-02024-w
-
Authors
Kolvenbach, Andreas https://orcid.org/0000-0002-9707-6831
Palumbieri, Maria Dilia https://orcid.org/0000-0002-0462-844X
Colby, Thomas
Nadarajan, Diyaraj
Bode, Remo https://orcid.org/0009-0009-6862-3531
Matić, Ivan https://orcid.org/0000-0003-0170-7991
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 19 June 2025
First Online: 9 July 2025
Change Date: 21 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41589-025-02024-w
Competing interests
: I.M. declares that Max Planck Innovation, which is responsible for technology transfer from Max Planck Institutes, has licensed the antibody AbD43647 to Bio-Rad Laboratories, which markets it for research purposes. I.M., A.K. and M.D.P. are named as inventors on a pending patent application related to the work described in this manuscript. The remaining authors declare no competing interests.
: All authors fully fulfilled the criteria for authorship required by Nature Portfolio, as their participation was essential for the design and implementation of the study. Roles and responsibilities were agreed among authors ahead of the research. This research does not result in stigmatization, discrimination, incrimination or personal risk to researchers.
